Analyst consensus rating
4D Molecular Therapeutics Analyst Rating: Strong Buy
Direct answer
4D Molecular Therapeutics's consensus rating is Strong Buy.
11 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $28.09.
Forecast evidence checked October 19, 2026.
Get free 4D Molecular Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $12.14
- Average price target
- $28.09
- High price target
- $37.00
- Low price target
- $18.00
- Low target gap
- +48.3%
- Target upside
- +131.4%
- High target gap
- +204.8%
- Target range width
- 156.5%
- Consensus rating
- Strong Buy
- Analysts
- 11
- Evidence date
- October 19, 2026
- Valid through
- October 26, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for 4D Molecular Therapeutics?
4D Molecular Therapeutics has a verified Strong Buy consensus. The same dataset has an average price target of $28.09.
How far are 4D Molecular Therapeutics's low and high targets from the recorded price?
The low target implies +48.3%, while the high target implies +204.8%.
How many analysts are included in 4D Molecular Therapeutics's consensus?
The verified consensus includes 11 analysts.
How is 4D Molecular Therapeutics's target upside or downside calculated?
The average target of $28.09 is divided by the recorded price of $12.14, then one is subtracted to produce +131.4%. This does not guarantee a future return.
When was 4D Molecular Therapeutics's analyst forecast verified?
The data was verified on 2026-10-19. The dataset is valid through 2026-10-26.